GEA
LCTX icon

Glen Eagle Advisors’s Lineage Cell Therapeutics LCTX Stock Holding History

Glen Eagle Advisors’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-500
Closed -$1.26K – 1020
2021
Q3 		$1.26K Hold
500
– – ﹤0.01% 975
2021
Q2 		$1.43K Hold
500
– – ﹤0.01% 957
2021
Q1 		$1.18K Hold
500
– – ﹤0.01% 929
2020
Q4 		$880 Hold
500
– – ﹤0.01% 916
2020
Q3 		$468 Hold
500
– – ﹤0.01% 888
2020
Q2 		$435 Sell
500
-613
-55% -$540 ﹤0.01% 860
2020
Q1 		$922 Sell
1,113
-750
-40% -$747 ﹤0.01% 759
2019
Q4 		$1.66K Hold
1,863
– – ﹤0.01% 795
2019
Q3 		$1.83K Buy
+1,863
New +$1.93K ﹤0.01% 714

Other funds holding LCTX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.47T AUM 27.86% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return